GPCR, an ecosystem designed to bring together stakeholders interested in using G-Protein Coupled Receptors GPCR About John Azietaku John Teye Azietaku,PhD is a trained pharmacist, holding a Ph.D. in Drug Discovery committed to leveraging his expertise to enhance healthcare outcomes and contribute to the growth of the pharmaceutical GPCR About Cam Sinh Lu Cam Sinh Lu is a PhD student at Monash Institute of Pharmaceutical Sciences, Monash

Eleonora Comeo, PhD candidate at the University of Nottingham and the Monash Institute of Pharmaceutical Sciences, is developing fluorescent ligands to address that gap directly - tools designed to visualize Comeo is a PhD candidate jointly enrolled at the University of Nottingham and the Monash Institute of Pharmaceutical A trained medicinal chemist and pharmacist, her research focuses on the design and synthesis of fluorescent

Evi Kostenis "Pharmacist by training - PhD in Pharmacology - Postdoc at the NIH with Dr. Pharmacology at 7TM Pharma in Denmark; Full professor, department chair and director of the institute for pharmaceutical

Khaled Abdelrahman graduated in 2006 with a BSc in Pharmaceutical Sciences from Alexandria University He is also a Registered Pharmacist in Canada and held two of the most prestigious Clinician Postdoctoral

Christopoulos is the Professor of Analytical Pharmacology and the Dean of the Faculty of Pharmacy & Pharmaceutical In 2023, he was elected a Fellow of the Pharmaceutical Society of Australia. " Dr. companies to advance the understanding and application of allosteric modulation. - Arthur will work on designing Pharmaceutical Industry Experiences and GPCR History Arthur shared his experiences in the pharmaceutical the clinical context and dialing in the desired effect, as well as the significance of rational drug design

Khaled Abdelrahman graduated in 2006 with a BSc in Pharmaceutical Sciences from Alexandria University He is also a Registered Pharmacist in Canada and held two of the most prestigious Clinician Postdoctoral

Hoare now consults for biotech and pharmaceutical clients on GPCR data analysis, receptor binding kinetics The Neurocrin team had to confront an explanation no assay had been designed to find — and then built affinity at pH 7.4 vanished entirely at the physiological vesicle pH of 5.5 — the pattern recurs: assays designed data analyst and the founder of Pharmechanics LLC , a consultancy and data analysis company supporting pharmaceutical Hoare was a pharmacology leader in the pharmaceutical industry for 15 years at Neurocrine Biosciences

(s) Brian Arey - Part 2: GPCR Drug Discovery and the Science Nobody Publishes Drug discovery in the pharmaceutical In this conversation, Arey traces the full arc of how a pharmaceutical research program is born, resourced About the Guest Brian Arey is a pharmacologist and physiologist with over 25 years of pharmaceutical Arey calls this one of the most important and least instinctive skills in pharmaceutical research - and He then moved to work in the pharmaceutical industry where he has held positions of increasing responsibility

ABOUT THE GUEST David Gloriam is a professor at the University of Copenhagen's Department of Drug Design , where he leads a multidisciplinary research group working across data science, computational drug design Until that pathway-level map is built, designing genuinely biased drugs remains a hypothesis in search Welcome and introduction of David Gloriam 02:23 Career origins - from childhood medicine ambitions to pharmaceutical University of Copenhagen where he leads a research cluster for GPCR function and drug discovery and a Pharmaceutical

Maria Majellaro earned her degree in Pharmaceutical Chemistry and Technology from the University of Bari Ligands in GPCR Research GPCRs are one of the most important families of therapeutic targets in the pharmaceutical dramatically improve how scientists measure ligand-receptor interactions, visualize binding in live cells, and design Custom Development Tailored fluorescent probes designed for unique research requirements.

“I think I don’t have a linear trajectory… the beauty of seeing molecule design and reactions—thinking you can create molecules—was really exciting.” – Alessandro Nicoli He studied pharmaceutical chemistry in Padua, where his fascination with molecular design first took shape. close to experimental structures, provided a powerful starting point for docking, dynamics, and ligand design—especially He obtained an MSc degree in Chemistry and Pharmaceutical Technology from the University of Padua (Italy

over another depending on how it is engaged - is now a central concept in GPCR pharmacology and drug design Florida State University before postdoctoral research at Northwestern, and has spent over 25 years in pharmaceutical classes The physiologist's approach to mechanistic drug discovery The erosion of pharmacology training in pharmaceutical for a therapeutic strategy built around modulators that can be combined, rather than single agents designed He then moved to work in the pharmaceutical industry where he has held positions of increasing responsibility

ABOUT THE GUEST Annette Gilchrist is Associate Professor of Pharmaceutical Sciences at Midwestern University agonism - a first-in-kind finding at wild-type FFA2 and its implications for biased ligand campaign design The aha moment was not the result itself but recognizing what it meant for how you could design the campaign It was not the experiment she had designed. Gilchrist is also an associate professor at the Department of Pharmaceutical Sciences.

Sokhom Pin shares how he built a biotech career around GPCRs, designed a custom PhD path, and led teams Designing a Non-Traditional PhD While working full-time, Sokhom architected a one-of-a-kind PhD program Sokhom Pin Sokhom Pin is a receptor pharmacologist with over 20 years of drug discovery research in the pharmaceutical

Alexander Hauser is a postdoctoral researcher at the University of Copenhagen's Department of Drug Design This has direct implications for how drug safety is assessed and how clinical trials are designed. 2. The patient impact requires the clinician's voice in the design phase. 6. During his Ph.D. with David Gloriam at the Department of Drug Design and Pharmacology in Copenhagen, He received the “HC Ørsted Research talent prize” and “Bayer Pharmaceuticals Ph.D.

internalization with pHSense pHSense™ probes are optimized reagents for plate readers, specifically designed Whether you’re decoding signaling pathways or designing the next generation of therapeutics, Revvity View Reagents Explore Revvity’s GPCR Assay Technologies Tools designed to illuminate every step of GPCR She has been leading collaborative projects with public research institutes and pharmaceutical companies A Tool Designed for Real Research Needs Built on more than two decades of GPCR assay innovation, pHSense

How an integrated training and lab structure at Monash Institute of Pharmaceutical Sciences fosters innovation Professor at Monash University and Deputy Theme Leader of Drug Discovery Biology at Monash Institute of Pharmaceutical More about Michelle Halls Monash Institute of Pharmaceutical Sciences Bluesky LinkedIn Articles about

GPCR pharmacology, receptor signaling, and drug discovery evolved inside one of the world’s largest pharmaceutical Serendipity Depends on Experimental Design and System Choice . understanding receptor activation in patients, but requires realistic views of effect sizes and trial design

Christopoulos is the Professor of Analytical Pharmacology and the Dean of the Faculty of Pharmacy & Pharmaceutical In 2023, he was elected a Fellow of the Pharmaceutical Society of Australia. " Dr. Lastly, they discussed the growth and development of the Monash Institute of Pharmaceutical Sciences, They also discussed the disruption within the pharmaceutical sector, the importance of workforce development

Christopoulos is the Professor of Analytical Pharmacology and the Dean of the Faculty of Pharmacy & Pharmaceutical In 2023, he was elected a Fellow of the Pharmaceutical Society of Australia. " Dr. Lastly, they discussed the growth and development of the Monash Institute of Pharmaceutical Sciences, They also discussed the disruption within the pharmaceutical sector, the importance of workforce development

understand how and where these compounds interact with the receptor, paving the way for structure-based drug design He received his Ph.D. in Pharmaceutics from the University of Minnesota in 2022, studying the pharmacokinetics

A conversation with Charlotte Crauwels exploring computational protein design, hybrid GPCR constructs Charlotte Crauwels’ research focuses on building computational pipelines that guide the rational design Her research centers on developing computational pipelines that guide the design of hybrid or chimeric I would define myself as a computational protein designer focusing on GPCRs. But designing these hybrids is difficult.

She has worked across pharmaceutical, biotechnology, and academic settings, including a research placement This reframes the design challenge for RAMP-selective compounds: the differences between receptor complexes

I then started my career at Evotec before moving to Domain Therapeutics (called Faust pharmaceutical

Struthers co-founded and serves as board chair at Radionetics Oncology, a pharmaceutical company focused

By the end of 2021, I moved back to Germany and joined the pharmaceutical chemistry group of Peter Kolb

These investigations have enabled him to foster strong collaborations with the pharmaceutical industry

Angers established his independent research program in the Department of Pharmaceutical Sciences at the

In 2021, I joined the Ferring Research Institute of Ferring Pharmaceuticals in San Diego as a scientist

and Better Medicines Theme Leader of the Neuromedicines Discovery Centre at the Monash Institute of Pharmaceutical